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Capillary malformation (CM), or “port-wine stain,” is a common cutaneous vascular anomaly that initially appears
as a red macular stain that darkens over years. CM also occurs in several combined vascular anomalies that exhibit
hypertrophy, such as Sturge-Weber syndrome, Klippel-Trenaunay syndrome, and Parkes Weber syndrome. Occa-
sional familial segregation of CM suggests that there is genetic susceptibility, underscored by the identification of
a large locus, CMC1, on chromosome 5q. We used genetic fine mapping with polymorphic markers to reduce the
size of the CMC1 locus. A positional candidate gene, RASA1, encoding p120-RasGAP, was screened for mutations
in 17 families. Heterozygous inactivating RASA1 mutations were detected in six families manifesting atypical CMs
that were multiple, small, round to oval in shape, and pinkish red in color. In addition to CM, either arteriovenous
malformation, arteriovenous fistula, or Parkes Weber syndrome was documented in all the families with a mutation.
We named this newly identified association caused by RASA1 mutations “CM-AVM,” for capillary malformation–
arteriovenous malformation. The phenotypic variability can be explained by the involvement of p120-RasGAP in
signaling for various growth factor receptors that control proliferation, migration, and survival of several cell types,
including vascular endothelial cells.
Introduction
Dermal vascular development involves penetration of
capillary vessels that is induced by vascular endothelial
growth factor (VEGF) secreted by keratinocytes in the
avascular epidermis (Brown et al. 1992; Ballaun et al.
1995). This invasion and the subsequent arterial differ-
entiation is also guided by VEGF originating from sen-
sory nerves in the dermis (Mukouyama et al. 2002).
Defective cutaneous vascular development manifests as
malformed vessels that vary in size, location, blood flow,
and clinical severity (Mulliken and Glowacki 1982).
Capillary malformation (CM), or “port-wine stain,”
(MIM 163000) is the most common vascular malfor-
mation, occurring in 0.3% of newborns (Jacobs and
Walton 1976). CM is a flat, cutaneous, slow-flow lesion
that is composed of dermal capillary-venular–like chan-
nels that are dilated and/or increased in number (Jacobs
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and Walton 1976; Barsky et al. 1980). Arteriovenous
malformation (AVM) and arteriovenous fistula (AVF)
are fast-flow vascular anomalies that can arise in skin,
muscle, bone, internal organs, and the brain and can
cause life-threatening complications such as bleeding,
congestive heart failure, or neurologic consequences
(Mulliken and Young 1988). Parkes Weber syndrome is
characterized by a cutaneous blush with underlying mul-
tiple micro-AVFs, in association with soft-tissue and
skeletal hypertrophy of the affected limb (Mulliken and
Young 1988). Sturge-Weber syndrome can present with
fast-flow leptomeningeal and choroid anomalies in as-
sociation with a facial CM involving the V1 dermatomic
area. Klippel-Trenaunay syndrome manifests as a slow-
flow capillary lymphaticovenous malformation most
commonly affecting lower extremities with soft-tissue
hypertrophy.
In a previous study of 13 families with familial CM,
we identified a susceptibility locus, CMC1, on chro-
mosome 5q14-21, with a minimally linked region of 23
cM between markers D5S1962 and D5S652 (Eerola et
al. 2002). In this study, a new family (family CM45)
(figs. 1A and 2) made it possible to narrow the locus
to 5 cM between markers D5S459 and GATA5F09. This
interval contains eight characterized genes, three of
which, RASA1, EDIL3 (EGF-like repeats and discoidin
I–like domains 3), and MEF2C (myocyte enhancer fac-
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Figure 1 Photographs of vascular malformations linked to RASA1 mutations. Individual numbers refer to pedigrees in figure 2. A,
Atypical inherited pink-to-red, round-to-oval CMs (arrows) (patients CM45 III-8, CM45 III-15, and CM45 IV-2, CM8 III-4, and CM8 II-6);
patient CM20 III-1, with a circumscribed nasal AVM and a cutaneous capillary blush (arrowhead); patient PW1 III-1, with Parkes Weber
syndrome in the lower limb (arrows). B, Photographs of CMs not linked to RASA1 mutations. Typical red-purple facial CM (patient PW1 II-
5); typical red CM of the neck (patient PW1 I-3).
tor-2C), were considered to be candidates of functional
interest.
The RASA1 gene codes for p120-RasGTPase–acti-
vating protein (p120-RasGAP). This is a modular pro-
tein of 1,047 amino acids that contains two Src ho-
mology 2 (SH2) domains and one Src homology 3 (SH3)
domain in the N-terminal region, a pleckstrin homology
(PH) domain, and a protein kinase conserved region 2
in the central region, as well as a RasGTPase-activat-
ing domain in the C-terminal region (fig. 4A) (Tra-
hey and McCormick 1987; Glanzer et al. 2002).
p120-RasGAP’s best-known function is as a negative
regulator of the Ras/MAPK-signaling pathway, which
mediates cellular growth, differentiation, and prolifer-
ation from various receptor tyrosine kinases (RTKs) on
cell surfaces (fig. 5) (Ballester et al. 1990; Gibbs et al.
1990; Clark et al. 1993). p120-RasGAP and the other
three known GAPs—NF1, GAPM1, and GAP1-like
protein—switch the active GTP-bound Ras to the in-
active GDP-bound form (Martin et al. 1990; Xu et al.
1990; Maekawa et al. 1994; Cullen et al. 1995). Effec-
tor functions downstream of RTKs have also been pro-
posed for p120-RasGAP—for example, via the associ-
ation with p190-RhoGAP that directs signaling to the
cytoskeleton (Settleman et al. 1992). In addition, p120-
RasGAP binds to Rap1a (Frech et al. 1990; Hata et al.
1990), which has been shown to be involved in integrin-
mediated cellular adhesion (Caron et al. 2000; Katagiri
et al. 2000; Reedquist et al. 2000). Mutations that make
Ras constitutively active and resistant to GAPs are often
found in malignant tumors (Bos 1989). Inactivating mu-
tations of the GAP proteins, in turn, can also lead to
inordinately active Ras signaling and tumorigenesis, as
in neurofibromatosis, caused by mutations in the NF1
gene (Cawthon et al. 1990; Viskochil et al. 1990). Mu-
tations in p120-RasGAP have also been implicated in
basal cell carcinoma (Friedman et al. 1993). However,
RASA1-deficient murine embryos exhibited early de-
velopmental arrest at E9.5 due to severe vascular defects
but exhibited no signs of cellular proliferation (Hen-
kemeyer et al. 1995).
Subjects and Methods
Subjects
Informed consent was obtained from all subjects par-
ticipating in the study, as approved by the ethics com-
mittee of the medical faculty of Universite´ Catholique
de Louvain, Brussels, Belgium. Families CM8, CM11,
1242 Am. J. Hum. Genet. 73:1240–1249, 2003
Figure 2 Pedigrees, vascular phenotypes, and cosegregation of the identified mutations. Pedigrees of families with detectable RASA1
mutations are shown in order of occurrence of corresponding mutation in the RASA1 gene. Numbered individuals were screened for mutations.
The number of lesions is in italic superscript. In families PW1, CM45, CM20, and CM41, cosegregation of deletional mutations with the
phenotype was performed using radioactive size-difference gel electrophoresis. In family CM8, the presence of RASA1c.1336CrT was detected
by Sau3A1 restriction digestion. The mutation destroys a Sau3A1 restriction-enzyme cutting site that normally splits the 223-bp allele into 134-
bp and 89-bp fragments. In family CM11, the allele containing RASA1c.1619GrA yielded a 214-bp fragment in mutation carriers only, in
addition to the wild-type control fragment of 485 bp in allele-specific PCR. Question marks indicate that the number of CMs is unknown.
RASA1c.475_476delCT and RASA1c.2336_2337delGC were de novo mutations. Altogether, four carriers were identified.
and CM20 have been reported elsewhere (as families C,
D, and E, respectively) (Eerola et al. 2002). The cuta-
neous vascular lesions varied in appearance from a sin-
gle, moderately large, pink macular stain in the nucha
or central forehead to a single, purple-red lesion of var-
iable shape and size, often located on the face (figs. 1
and 3), to multiple small, round-to-oval, pinkish red
lesions, mainly present on an extremity (figs. 1 and 2).
Some patients also had CM-associated vascular anom-
alies and soft- and skeletal-tissue hypertrophy, charac-
terized as follows: In family PW1, patient III-1 had
Parkes Weber syndrome (fig. 1A), and patient III-2 had
an intracranial AVM, as well as multiple cutaneous CMs.
In family CM45, patient III-15 had an intracranial AVM
and five cutaneous CMs, whereas patient IV-11 had a
cutaneous AVM of the ankle and three cutaneous CMs.
In family CM8, patient III-11 had a left maxillary AVM
causing skeletal hypertrophy and an extensive hemifacial
CM with soft-tissue hypertrophy, and patient III-12 had
a lower labial CM with hypertrophy and an intraman-
dibular AVM causing occlusal distortion. In family
CM20, patient III-1 had a deep facial AVM with an
overlying cutaneous capillary stain (fig. 1A). In family
CM41, patient III-10 had an AVM of the forehead and
three small cutaneous CMs, and patient IV-10 had a
stage I cutaneous AVM of the right fifth finger. In family
CM11, patient III-5 had a facial capillary stain and hy-
pertrophy distal to an AVF, which was located between
the left carotid artery and the jugular vein and caused
cardiac overload, requiring medication since infancy.
Figure 3 Pedigrees of families without detectable RASA1 mutations. Numbered individuals were screened for mutations. The number of
lesions is in italic superscript.
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This patient also had a small CM on the left wrist. In
family KT1, patients II-1 and III-2 had Klippel-Tren-
aunay syndrome in a lower extremity, and, in family
CM16, patient IV-4 had Sturge-Weber syndrome. The
two affected individuals in family AVM2 only had an
AVM and no cutaneous CM.
Reduction of the CMC1 Locus
Linkage to the CMC1 locus was tested in family
CM45 with 17 polymorphic markers: D5S1962,
D5S646, D5S1501, D5S641, D5S2029, D5S2094,
D5S428, D5S459, D5S617, D5S2103, D5S1725,
D5S401, D5S2044, D5S2100, GATA5F09, AFM205,
and D5S652, as described elsewhere (Eerola et al. 2002).
SSCP and Heteroduplex Analyses
The genomic sequences containing the RASA1 gene
were identified with the RASA1 mRNA sequence
(NM_002890.1) by performing a BLAST homology
search on the human genome sequence at the National
Center for Biotechnology Information (NCBI) En-
trez BLAST server. The working draft sequence
NT_037660.1 for homo sapiens chromosome 5, which
contains the gene, was retrieved from the NCBI Entrez
database. To amplify all the 25 exons, including exon-
intron boundaries, 27 sets of primers (available on re-
quest) were designed. The isoform-2–specific exon 1 was
also screened. PCR reactions, subsequent SSCP and het-
eroduplex analyses, and direct sequencing were per-
formed, as described elsewhere (Brouillard et al. 2002).
Numbering of nucleotides is based on the cDNA se-
quence NM_002890.1 with the adenosine of the ATG
start codon marked as 1.
Cosegregation Analysis
The fragments with detected deletional mutations
were amplified by radioactive PCR from genomic DNA
from all family members and were analyzed by size-
difference gel electrophoresis to detect cosegrega-
tion (families PW1, CM45, CM20, and CM41) (fig. 2).
Cosegregation of the mutation RASA1c.1336CrT
(p.Q446X), which destroys a Sau3A1 restriction-enzyme
cutting site, was screened by Sau3A1 (Promega) diges-
tion of exon 10 genomic amplicons for all individuals
in family CM8 (fig. 2), according to the manufacturer’s
instructions. Mutation RASA1c.1619GrA (p.C540Y)
in family CM11 did not change any restriction-enzyme
cutting site. Thus, it was screened by allele-specific PCR
(fig. 2) (primers available on request). A group of 105
unrelated, healthy controls was also screened for all
mutations.
Results
Identification of RASA1 Mutations
SSCP and heteroduplex analyses were performed on
DNA samples from 17 families manifesting cutaneous
CM to screen all 26 exons and the exon-intron bound-
aries of the gene for RASA1 mutations. RASA1 muta-
tions were found in six families. None of these mutations
was identified in the 105 healthy controls. Of the 11
families without a detectable RASA1 mutation, 6 (KT1,
CM2, CM13, CM16, CM18, and CM31) yielded a neg-
ative LOD score, and 2 small families (CM5 and CM10)
were uninformative at the CMC1 locus in multipoint link-
age analysis (90% penetrance; 0.3% phenocopy rate). In
family CM6, one affected individual (III-6) excluded the
locus. No linkage data was available for family CM34,
and family AVM2 was uninformative for linkage analysis.
The identified alterations included four deletions
in the coding region, RASA1c.475_476delCT,
RASA1c.512delT, RASA1c.1579_1582delGTCT, and
RASA1c.2336_2337delGC, and two substitutions,
RASA1c.1336CrT, leading to a nonsense mutation,
p.Q446X, and RASA1c.1619GrA, resulting in cysteine-
to-tyrosine substitution at amino acid 540 (p.C540Y) (fig.
4A). The deletions caused reading-frame shifts and sub-
sequent premature stop codons, predicted to result in a
truncated protein (fig. 4A). The only amino acid substi-
tution, p.C540Y, occurred in the PH domain (fig. 4),
which has been shown to regulate interaction between
p120-RasGap and RAS (Drugan et al. 2000). The adja-
cent C-terminal amino acid phenylalanine (541) is highly
conserved in PH domains (fig. 4B). Cysteine is present at
position 540 in 37 (15%) of 201 of the PH domains in
the PROSITE database, whereas tyrosine at this position
is only found in the PH domains of the guanine-nucleo-
tide–releasing protein (RasGRF1/CDC25) of three species
(fig. 4B). It is interesting that, unlike the PH domain of
p120-RasGAP, the PH domain of RasGRF1/CDC25 did
not inhibit Ras-induced transformation in an overex-
pression experiment on NIH3T3 cells (Drugan et al.
2000). Thus, the RASA1c.1619GrA mutation may also
result in a functionless p120-RasGap; however, further
functional studies are needed to look at the effect of this
change on function. Two of the six mutations occurred
de novo (family PW1 and CM41) (fig. 2).
RASA1 Mutations Cause a Distinct Phenotype: CM-
AVM
Mutations cosegregated with vascular malformations
in all six families (fig. 2). The affected individuals ex-
hibited atypical CMs, usually characterized as pink-to-
red, multiple, small (1–2 cm in diameter), round-to-oval
lesions (fig. 1A). In each family, at least one individual
had a high-flow lesion—either a soft-tissue ( ),np 4
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Figure 4 A, Schematic presentation of identified RASA1 mutations. Four deletional mutations—RASA1c.475_476delCT,RASA1c.512delT,
RASA1c.1579_1582delGTCT, and RASA1c.2336_2337delGC—cause frame shifts and subsequent premature stop codons. Resultinghypothetical
proteins are illustrated. RASA1c.1336CrT is a nonsense mutation, whereas RASA1c.1619GrA results in a Cys-540-Tyr substitution in the PH
domain at position 540. SH2 p Src homology 2 domain; SH3 p Src homology 3 domain; C2 p protein kinase conserved region 2; RASGAP
p rasGTPase-activating domain. Altered amino acid sequences due to frame shifts are shown by diagonal lines. B, Multiple alignment of PH
domains. The figure illustrates the alignment of 15 PH-domain amino acid sequences around the p.C540Y mutation. Highly conserved phe-
nylalanine is represented by a boldface F. Only 12 of 37 PH domains containing the mutated cysteine p.C540Y at this position are shown
(box). Also shown are the three orthologous PH-domain sequences, all from RASGRF1, that contain a tyrosine (Y) at this position.
brain ( ), or skeletal ( ) AVM or an AVFnp 2 np 2
( ) concurrently with an atypical CM. The AVFnp 1
between the ipsilateral carotid artery and the jugular
vein, as well as a skeletal AVM of the face, were asso-
ciated with overgrowth. In addition, one patient (PW1
III-1) was diagnosed as having Parkes Weber syndrome,
with multiple micro-AVFs and soft- and skeletal-tissue
hypertrophy of the affected limb (fig. 1A). A mutation
was found in four individuals who had no obvious vas-
cular malformation, giving an overall penetrance of
89%. The eight phenocopies without a RASA1 mutation
identified in these families had either a single pink CM
of the nuchal region (4/8) (fig. 1B) or a single purple-
red lesion reminiscent of common, sporadic CM (4/8).
Four of the families with a RASA1 mutation were from
Belgium; one was from the United States; and one was
from Canada.
In 9 of the 11 families without a detectable RASA1
mutation, the cutaneous vascular lesions either were lo-
cated in the nuchal region or they were moderately large
or purple-red CMs of variable shape and location. In
one of these families, two individuals had Klippel-Tren-
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Figure 5 Signaling pathways implicating p120-RasGAP. Growth-factor binding to RTKs on the cell surface activates the Ras/MAPK-
signaling pathway, which mediates signals to transcription factors in the nucleus. Changes in gene expression lead to cellular responses, such
as differentiation and proliferation. p120-RasGAP (RasGAP) downregulates Ras signaling by catalyzing intrinsic GTPase activity of Ras. p120-
RasGAP also is implicated in signaling to the cytoskeleton by binding Rap1a and/or p190-RhoGAP (RhoGAP).
aunay syndrome, and, in another, one individual had
Sturge-Weber syndrome. In family CM6, some individ-
uals had multiple small, pink-to-red CMs. No associated
AVFs or AVMs were observed in these 10 families. In
the 11th family, the two affected individuals had an
AVM without cutaneous CM. The identification of atyp-
ical round-to-oval CMs and their association with high-
flow arterial lesions and soft- and skeletal-tissue hyper-
trophy constitutes a newly recognized clinical and
genetic entity that we named “CM-AVM,” for capillary
malformation–arteriovenous malformation.
Discussion
Mosaic mice composed of wild-type and p120-RasGap-
deficient cells exhibit abnormal angiogenesis due to en-
dothelial cell dysfunction in the reorganization of the
capillary rete to a mature vascular network (Henke-
meyer et al. 1995). Subsequent studies of RASA1-defi-
cient cells have shown that p120-RasGAP is required for
properly directed cellular movement (Kulkarni et al.
2000). The wide range of growth-factor receptors, the
signaling of which can be affected by RASA1 mutations,
probably explains the murine phenotype, as well as the
human phenotypic variability described in this article.
The pathogenesis of the cutaneous lesions of CM-AVM
could involve a defective migratory response of endo-
thelial cells to angiogenic factors, presumably a result of
VEGF secreted by keratinocytes and sensory nerves dur-
ing the development of dermal vasculature. The aberrant
response to secreted VEGF could also explain an earlier
observation of misalignment of capillaries and cutaneous
nerves in CM (Smoller and Rosen 1986; Rydh et al.
1991). Furthermore, altered VEGF response could con-
tribute to the abnormal arteriogenesis, resulting in
AVMs, AVFs, and soft-tissue or skeletal hypertrophy.
The formation of direct shunts in AVMs and AVFs could
also be due to dysregulated signaling of EphB-receptor–
mediated pathways in which p120-RasGAP has a role
(Wang et al. 1998; Kim et al. 2002; Nagashima et al.
2002).
The localized nature of the vascular anomalies and
incomplete penetrance of the mutations may suggest
that a somatic second hit, resulting in a complete lack
of activity of p120-RasGAP, could be necessary for a
lesion to develop, as has been shown for glomulin in
glomuvenous malformations (Brouillard et al. 2002).
Thus, the variable phenotypes caused by the RASA1
mutations might reflect the extent and identity of the
affected cellular population. The soft-tissue and skeletal
overgrowth could be caused by a complete loss of func-
tion of p120-RasGAP in mesenchymal cells, which
would intensify the cellular effects of mitogens, such as
FGF and EGF.
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Another inherited vascular malformation, cerebral
capillary malformation (CCM [MIM 116860]), has also
been linked to misregulated Ras signaling (Laberge-le
Couteulx et al. 1999; Sahoo et al. 1999). The mutated
protein, KRIT1 (Krev interaction trapped-1), was orig-
inally identified as a binding partner of Rap1a (Sere-
briiskii et al. 1997), an antagonist of Ras transformation
(fig. 5) (Kitayama et al. 1989). CCM lesions are located
in the cerebral parenchyma and are composed of dilated
capillary-like vessels and/or large cavernous channels
lined by thin basal lamina. The number of lesions tends
to increase over time (Labauge et al. 2000, 2001), which
might be a result of the identified slight upregulation in
the proliferative capacity of CCM-derived endothelial
cells (Notelet et al. 1997). KRIT1 has also been shown
to bind ICAP1 (integrin cytoplasmic domain-associated
protein-1) (Zhang et al. 2001; Gunel et al. 2002; Za-
wistowski et al. 2002), a protein that links integrins and
the actin cytoskeleton (Chang et al. 1997), which im-
plies a process of integrin-signaling–mediated cellular
adhesion in the pathogenesis of CCM (fig. 5). It is pos-
sible that CM-AVM and CCM are due to similar cellular
processes, since p120-RasGAP can bind Rap1a, which
is known to have an important role in integrin-mediated
cellular adhesion (Caron et al. 2000; Katagiri et al.
2000; Reedquist et al. 2000; Nagashima et al. 2002).
It is interesting that, in certain CCM families carrying
KRIT1 mutations, some members also have cutaneous
lesions characterized as hyperkeratotic capillary-venous
malformations (Labauge et al. 1999; Eerola et al. 2000).
Our data show that an atypical cutaneous CM can
be an indicator of a genetic susceptibility to more se-
vere vascular high-flow anomalies—namely, AVM and
AVF—which can occur alone or as part of a combined
disorder, such as in Parkes Weber syndrome. Latent in-
tracranial AVM and carotid AVF, which may cause life-
threatening hemorrhaging, could be identified by
screening at-risk individuals by MRI or echo-Doppler
examination. Since four of the families were observed
in the small Belgian population, many others probably
exist. Extended studies are needed to further charac-
terize the phenotypic variability in CM-AVM, to test
the hypothesis of two-hit activation of the pathogenesis
of the lesions, and to dissect the specific pathways al-
tered by p120-RasGAP mutations. In theory, Ras ac-
tivity modulators could have a therapeutic potential in
normalizing the regulation of the Ras signaling pathway
in these patients.
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